Adherium announces new partnership with leading US allergy and asthma group

Latest News

Australian digital health company Adherium (ASX:ADR) has announced a new partnership in which SENTA Partners has agreed to roll out the Hailie platform to its base of clinics and patients across their network.

SENTA is one of the largest specialty allergy and asthma groups in the US. It boasts a network of 48 locations in six states with 88 allergy, asthma and ENT physicians, physician assistants and nurse practitioners.

Adherium and SENTA Partners have prepared an implementation plan commencing this month with an initial rollout in Georgia under the direction of a lead physician, practice administrator and nurse practitioner.

Adherium said that to support SENTA’s rollout, it is investing in and building up the US implementation team, including clinical applications, technical support and customer service staff. Expansion to additional SENTA clinic locations is planned for later this calendar year. With sufficient US sensor inventory and a responsive contract manufacturer, Adherium is fully prepared to meet the expected growing demand.

"This important partnership marks another US commercialisation milestone as we strive to rapidly build large-scale product roll out. We are committed to our partner’s success and as such are investing with US-based, on-the-ground implementation staff to execute and achieve our commercial objectives under our partner agreements. Together, Adherium and SENTA Partners aim to make a profound impact on improving patients’ lives and respiratory care," said Adherium CEO Rick Legleiter.

Hailie enables doctors to bill for long-term, remote patient management under established US reimbursement codes. Adherium gets paid for sensor sales and by receiving monthly, per-patient fees for generating and transmitting respiratory data.

The Hailie platform, comprising sensor technology, a user-friendly app, a clinician portal and a cloud-based data solution, helps patients manage their asthma conditions actively.